These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7579436)

  • 1. Aggressive treatment for postcardiac transplant lymphoproliferation.
    Swinnen LJ; Mullen GM; Carr TJ; Costanzo MR; Fisher RI
    Blood; 1995 Nov; 86(9):3333-40. PubMed ID: 7579436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable remission after aggressive chemotherapy for post-cardiac transplant lymphoproliferation.
    Swinnen LJ
    Leuk Lymphoma; 1997 Dec; 28(1-2):89-101. PubMed ID: 9498708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
    Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
    J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
    Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC
    J Clin Oncol; 1994 Oct; 12(10):2153-9. PubMed ID: 7523607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation.
    Watts RG; Hilliard LM; Berkow RL
    J Pediatr Hematol Oncol; 2002 Nov; 24(8):622-6. PubMed ID: 12439033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
    Fisher RI; Longo DL; DeVita VT; Hubbard SM; Miller TP; Young RC
    Ann Oncol; 1991 Jan; 2 Suppl 1():33-5. PubMed ID: 1710487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.
    Mamzer-Bruneel MF; Lomé C; Morelon E; Levy V; Bourquelot P; Jacobs F; Gessain A; Mac Intyre E; Brousse N; Kreis H; Hermine O
    J Clin Oncol; 2000 Nov; 18(21):3622-32. PubMed ID: 11054435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients.
    Chen YC; Ho CL; Kao WY; Hwang JM; Sheu LF; Chao TY
    Ann Hematol; 2001 Nov; 80(11):647-52. PubMed ID: 11757723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
    Gordon LI; Anderson J; Habermann TM; Winter JN; Glick J; Schilder RJ; Cassileth P
    J Clin Oncol; 1996 Apr; 14(4):1275-81. PubMed ID: 8648384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.
    Prokocimer M; Modan M; Rusoshansky S; Bairey O; Shaklai M
    Anticancer Res; 1989; 9(4):1233-5. PubMed ID: 2479327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.
    Swinnen LJ; LeBlanc M; Grogan TM; Gordon LI; Stiff PJ; Miller AM; Kasamon Y; Miller TP; Fisher RI
    Transplantation; 2008 Jul; 86(2):215-22. PubMed ID: 18645482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
    Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
    J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
    Reece DE; Barnett MJ; Shepherd JD; Hogge DE; Klasa RJ; Nantel SH; Sutherland HJ; Klingemann HG; Fairey RN; Voss NJ
    Blood; 1995 Jul; 86(2):451-6. PubMed ID: 7541661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in chemotherapy for large cell lymphoma.
    Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ProMACE-MOPP vs. ProMACE-CytaBOM polychemotherapies in the treatment of large-cell and unclassifiable non-Hodgkin's lymphomas].
    Pieresca C; Gobbi PG; Bertoloni D; Grignani G; Rossi A; Legnani MC; Giordano M
    Ann Ital Med Int; 1991; 6(3):267-72. PubMed ID: 1723289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.